Trimethoprim: Difference between revisions

	WikiDoc Resources for Trimethoprim
Articles
Most recent articles on Trimethoprim Most cited articles on Trimethoprim Review articles on Trimethoprim Articles on Trimethoprim in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Trimethoprim Images of Trimethoprim Photos of Trimethoprim Podcasts & MP3s on Trimethoprim Videos on Trimethoprim
Evidence Based Medicine
Cochrane Collaboration on Trimethoprim Bandolier on Trimethoprim TRIP on Trimethoprim
Clinical Trials
Ongoing Trials on Trimethoprim at Clinical Trials.gov Trial results on Trimethoprim Clinical Trials on Trimethoprim at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Trimethoprim NICE Guidance on Trimethoprim NHS PRODIGY Guidance FDA on Trimethoprim CDC on Trimethoprim
Books
Books on Trimethoprim
News
Trimethoprim in the news Be alerted to news on Trimethoprim News trends on Trimethoprim
Commentary
Blogs on Trimethoprim
Definitions
Definitions of Trimethoprim
Patient Resources / Community
Patient resources on Trimethoprim Discussion groups on Trimethoprim Patient Handouts on Trimethoprim Directions to Hospitals Treating Trimethoprim Risk calculators and risk factors for Trimethoprim
Healthcare Provider Resources
Symptoms of Trimethoprim Causes & Risk Factors for Trimethoprim Diagnostic studies for Trimethoprim Treatment of Trimethoprim
Continuing Medical Education (CME)
CME Programs on Trimethoprim
International
Trimethoprim en Espanol Trimethoprim en Francais
Business
Trimethoprim in the Marketplace Patents on Trimethoprim
Experimental / Informatics
List of terms related to Trimethoprim

Trimethoprim
Clinical data
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ; ;
Routes of; administration	Oral
ATC code	J01EA01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	90–100%
Metabolism	hepatic
Elimination half-life	8–10 hours
Excretion	renal 50–60%
Identifiers
	IUPAC name 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine;
CAS Number	738-70-5;
PubChem CID	5578;
DrugBank	APRD00103;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H18N4O3
Molar mass	290.32 g/mol

VisualWikitext

Revision as of 20:42, 8 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trimethoprim (INN) (IPA: Template:IPA) is a bacteriostatic antibiotic mainly used in the prophylaxis and treatment of urinary tract infections. It belongs to the class of chemotherapeutic agents known as dihydrofolate reductase inhibitors. Trimethoprim was formerly marketed by GlaxoWellcome under trade names including Proloprim, Monotrim and Triprim; but these trade names have been licensed to various generic pharmaceutical manufacturers. In clinical use it is often abbreviated TRI or TMP; its common laboratory abbreviation is W.

Mechanism of action

Trimethoprim acts by interfering with the action of bacterial dihydrofolate reductase, inhibiting synthesis of tetrahydrofolic acid. Tetrahydrofolic acid is an essential precursor in the de novo synthesis of the DNA nucleotide thymine. Bacteria are unable to take up folic acid from the environment (i.e. the infection host) and are thus dependent on their own de novo synthesis. Inhibition of the enzyme starves the bacteria of bases necessary for DNA replication.

Co-trimoxazole

Trimethoprim was commonly used in combination with sulfamethoxazole, a sulfonamide antibiotic, which inhibits an earlier step in the folate synthesis pathway (see diagram above). This combination, also known as co-trimoxazole, TMP-sulfa, or TMP-SMX, results in an in vitro synergistic antibacterial effect by inhibiting successive steps in folate synthesis, this claimed benefit was not seen in general clinical use.^[1] ^[2] Its use has been declining due to reports of sulfamethoxazole bone marrow toxicity, resistance and lack greater efficacy in treating common urine and chest infections,^[3]^[4]^[5]^[6] and side effects of antibacterial sulfonamides. As a consequence, the use of co-trimoxazole was restricted in 1995.^[7]

Clinical indications

Trimethoprim, used as monotherapy, is indicated for the prophylaxis and treatment of urinary tract infections (cystitis). Co-trimoxazole, with its greater efficacy against a limited number of bacteria, remains indicated for some infections; for example, it is used as prophylaxis in patients at risk for Pneumocystis jirovecii pneumonia (e.g. AIDS patients and those with some hematological malignancies) and as therapy in Whipple's disease.

Footnotes

↑ Brumfitt W, Hamilton-Miller JM (1993). "Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines". J Chemother. 5 (6): 465–9. PMID 8195839. Unknown parameter |month= ignored (help)
↑ Brumfitt W, Hamilton-Miller JM (1994). "Limitations of and indications for the use of co-trimoxazole". J Chemother. 6 (1): 3–11. PMID 8071675. Unknown parameter |month= ignored (help)
↑ Bean DC, Livermore DM, Papa I, Hall LM (2005). "Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man". J Antimicrob Chemother. 56 (5): 962–4. PMID 16150859. Unknown parameter |month= ignored (help)
↑ Felmingham D, Reinert RR, Hirakata Y, Rodloff A (2002). "Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin". J Antimicrob Chemother. 50 (Suppl S1): 25–37. PMID 12239226. Unknown parameter |month= ignored (help)
↑ Johnson JR, Manges AR, O'Bryan TT, Riley LW (2002). "A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis". Lancet. 359 (9325): 2249–51. PMID 12103291. Unknown parameter |month= ignored (help)
↑ Lawrenson RA, Logie JW (2001). "Antibiotic failure in the treatment of urinary tract infections in young women". J Antimicrob Chemother. 48 (6): 895–901. PMID 11733475. Unknown parameter |month= ignored (help) - suggest some small advantage in UTIs
↑ "Co-trimoxazole use restricted". Drug Ther Bull. 33 (12): 92–3. 1995. PMID 8777892. Unknown parameter |month= ignored (help)

External links

Nucleic acid inhibitors (PDF file).

Template:Sulfonamides and trimethoprim

de:Trimethoprim hu:Trimetoprim sk:Trimetoprim sv:Trimetoprim th:ไตรเมโทพริม

Template:WikiDoc Sources

[1] Brumfitt W, Hamilton-Miller JM (1993). "Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines". J Chemother. 5 (6): 465–9. PMID 8195839. Unknown parameter |month= ignored (help)

[2] Brumfitt W, Hamilton-Miller JM (1994). "Limitations of and indications for the use of co-trimoxazole". J Chemother. 6 (1): 3–11. PMID 8071675. Unknown parameter |month= ignored (help)

[3] Bean DC, Livermore DM, Papa I, Hall LM (2005). "Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man". J Antimicrob Chemother. 56 (5): 962–4. PMID 16150859. Unknown parameter |month= ignored (help)

[4] Felmingham D, Reinert RR, Hirakata Y, Rodloff A (2002). "Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin". J Antimicrob Chemother. 50 (Suppl S1): 25–37. PMID 12239226. Unknown parameter |month= ignored (help)

[5] Johnson JR, Manges AR, O'Bryan TT, Riley LW (2002). "A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis". Lancet. 359 (9325): 2249–51. PMID 12103291. Unknown parameter |month= ignored (help)

[6] Lawrenson RA, Logie JW (2001). "Antibiotic failure in the treatment of urinary tract infections in young women". J Antimicrob Chemother. 48 (6): 895–901. PMID 11733475. Unknown parameter |month= ignored (help) - suggest some small advantage in UTIs

[7] "Co-trimoxazole use restricted". Drug Ther Bull. 33 (12): 92–3. 1995. PMID 8777892. Unknown parameter |month= ignored (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

v t e Acne-treating agents (D10)
Topical agents	Azelaic acid • Benzoyl peroxide • Glycolic acid • Light therapy • Salicylic acid • Tea tree oil
Antibiotics	Clindamycin • Erythromycin • Sulfacetamide • Tetracyclines • Trimethoprim
Hormonal	Antiandrogens • Contraceptives
Retinoids	Adapalene • Isotretinoin • Tazarotene • Tretinoin

Revision as of 17:06, 20 August 2012 (view source) WikiBot (talk \| contribs) m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) ← Older edit	Revision as of 20:42, 8 January 2014 (view source) Gerald Chi (talk \| contribs) m (Changed protection level for "Trimethoprim" ([Edit=Allow only autoconfirmed users] (expires 20:42, 22 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 20:42, 22 January 2014 (UTC)))) Newer edit →
(No difference)

Clinical data

Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	J01EA01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	90–100%
Metabolism	hepatic
Elimination half-life	8–10 hours
Excretion	renal 50–60%
Identifiers
IUPAC name 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine
CAS Number	738-70-5
PubChem CID	5578
DrugBank	APRD00103
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₄H₁₈N₄O₃
Molar mass	290.32 g/mol